New hope for MDS patients: drug may cut need for platelet transfusions
NCT ID NCT04797000
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests a drug called eltrombopag in adults with a low-risk form of myelodysplastic syndromes (MDS) who regularly need platelet transfusions. The goal is to see if the drug can help patients go without transfusions for at least 8 weeks. The study involves 36 participants in Japan and compares the drug to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Narita, Chiba, 286-8523, Japan
-
Novartis Investigative Site
Kurume, Fukuoka, 830-8543, Japan
-
Novartis Investigative Site
Ohtake, Hiroshima, 739-0696, Japan
-
Novartis Investigative Site
Nishinomiya, Hyōgo, 663 8501, Japan
-
Novartis Investigative Site
Kanazawa, Ishikawa-ken, 920-8530, Japan
-
Novartis Investigative Site
Isehara, Kanagawa, 259-1193, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa, 221-0855, Japan
-
Novartis Investigative Site
Sendai, Miyagi, 9808574, Japan
-
Novartis Investigative Site
Nagasaki, Nagasaki, 852-8501, Japan
-
Novartis Investigative Site
Sakai, Osaka, 590-0197, Japan
-
Novartis Investigative Site
Bunkyo-ku, Tokyo, 113-8603, Japan
-
Novartis Investigative Site
Itabashi Ku, Tokyo, 173 8606, Japan
-
Novartis Investigative Site
Shimonoseki, Yamaguchi, 750-0061, Japan
-
Novartis Investigative Site
Aomori, 030 8553, Japan
-
Novartis Investigative Site
Chiba, 260-0852, Japan
-
Novartis Investigative Site
Fukushima, 9601295, Japan
-
Novartis Investigative Site
Gifu, 5008513, Japan
-
Novartis Investigative Site
Kumamoto, 860-0008, Japan
-
Novartis Investigative Site
Osaka, 5340021, Japan
-
Novartis Investigative Site
Yamagata, 990 9585, Japan
Conditions
Explore the condition pages connected to this study.